Autolus Therapeutics Reports Q1 2025 Financial Results

Autolus Therapeutics ( (AUTL) ) has issued an update.

Autolus Therapeutics reported its financial results for the first quarter of 2025, highlighting a net product revenue of $9.0 million from AUCATZYL® and securing marketing authorization from the U.K.’s MHRA. The company is advancing its clinical trials, including a Phase 2 trial for lupus nephritis and a Phase 1 trial for multiple sclerosis, with plans to dose the first patients by the end of 2025. Despite a net loss of $70.2 million for the quarter, Autolus remains well-capitalized to support its ongoing and planned clinical developments, aiming to expand its therapeutic reach and address significant unmet medical needs.

Spark’s Take on AUTL Stock

According to Spark, TipRanks’ AI Analyst, AUTL is a Neutral.

Autolus Therapeutics receives a low overall score due to financial struggles despite revenue growth. Technical indicators show limited upside, and valuation remains unattractive with negative earnings. The earnings call highlighted strategic achievements and a solid cash position, but financial challenges persist.

To see Spark’s full report on AUTL stock, click here.

More about Autolus Therapeutics

Autolus Therapeutics is an early commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering next-generation programmed T cell therapies. The company is primarily involved in the biopharmaceutical industry and is known for its product AUCATZYL®, which targets adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). Autolus is expanding its market presence with a focus on the U.S. and U.K. markets, leveraging its proprietary manufacturing and commercial infrastructure.

Average Trading Volume: 1,702,396

Technical Sentiment Signal: Sell

Current Market Cap: $314M

For an in-depth examination of AUTL stock, go to TipRanks’ Stock Analysis page.